• 1
    Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 3217.
  • 2
    Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide-or tumor lysatepulsed dendritic cells. Nat Med 1998; 4: 32832.
  • 3
    Jager E, Gnjatic S, Nagata Y et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 2000; 97: 12198203.
  • 4
    Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 90915.
  • 5
    Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 2006; 16: 11523.
  • 6
    Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182: 4499506.
  • 7
    Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 9429.
  • 8
    Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 1853843.
  • 9
    Loeffler M, Kruger JA, Reisfeld RA. Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res 2005; 65: 502730.
  • 10
    Wada S, Yoshimura K, Hipkiss EL et al. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res 2009; 69: 430918.
  • 11
    Ghiringhelli F, Larmonier N, Schmitt E et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004; 34: 33644.
  • 12
    Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25(interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999; 59: 312833.
  • 13
    Tawara I, Take Y, Uenaka A, Noguchi Y, Nakayama E. Sequential involvement of two distinct CD4+ regulatory T cells during the course of transplantable tumor growth and protection from 3-methylcholanthrene-induced tumorigenesis by CD25-depletion. Jpn J Cancer Res 2002; 93: 9116.
  • 14
    Yamaguchi T, Hirota K, Nagahama K et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 2007; 27: 14559.
  • 15
    Kojima H, Akaki J, Nakajima S, Kamei K, Tamesada M. Structural analysis of glycogen-like polysaccharides having macrophage-activating activity in extracts of Lentinula edodes mycelia. J Nat Med 2010; 64: 1623.
  • 16
    Tajima S, Saito Y, Suzuki I, Tokuda Y. Antibody treatment of breast cancer. Biotherapy (Tokyo) 2003; 17: 43746 (in Japanese).
  • 17
    Sugano N, Choji Y, Hibino Y, Yasumura S, Maeda H. Anticarcinogenic antion of an alcohol-insoluble fraction (LAP1) from culture medium of Lentinus edodes mycelia. Cancer Lett 1985; 27: 16.
  • 18
    Sugano N, Hibino Y, Choji Y, Maeda H. Anticarcinogenic actions of water-soluble and alcohol-insoluble fractions from culture medium of Lentinus edodes mycelia. Cancer Lett 1982; 17: 10914.
  • 19
    Ichikawa Y, Mizoguchi Y, Kobayashi K, Morisawa S. Effect of extract from culture medium of Lentinus edodes mycelia on intracellular calcium ion concentration in the peritoneal exudate exudate macrophages. J Tradit Med 1991; 8: 1626 (in Japanese).
  • 20
    Suzuki H, Iiyama K, Yoshida O, Yamazaki S, Yamamoto N, Toda S. Structural characterization of the immunoactive and antiviral water-solubilized lignin in an extract of the culture medium of Lentinus edodes mycelia (L.E.M.). Agric Biol Chem 1990; 54: 47987.
  • 21
    Yoshioka Y, Tamesada M, Nagayama A. The safety of excessive intake of the food containing extract of cultured Lentinula edodes mycelia (L.E.M.) in healthy adult volunteers. JCAM 2009; 6: 915 (in Japanese).
  • 22
    Yoshioka Y, Matsui Y, Kobayashi M et al. Safety evaluation of extract from cultured Lentinula edodes mycelia: study of acute toxicity, genotoxicity and inhibiting effect of drug-metabolizing enzme, cytochrome P-450 3A4. JCAM 2010; 7: 517 (in Japanese).
  • 23
    Harada M, Tamada K, Abe K et al. Characterization of B16 melanoma-specific cytotoxic T lymphocytes. Cancer Immunol Immunother 1998; 47: 198204.
  • 24
    Bloom MB, Perry-Lalley D, Robbins PF et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997; 185: 4539.
  • 25
    Kline J, Brown IE, Zha YY et al. Homeostatic proliferation plus reglatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res 2008; 14: 315667.
  • 26
    Matsushita N, Pilon-Thomas SA, Martin LM, Riker Al. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 2008; 333: 16779.
  • 27
    Wing K, Onishi Y, Prieto-Martin P et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322: 2715.
  • 28
    Lu L, Ma J, Wang X et al. Synergistic effect of TGF-beta superfamily members on the induction of Foxp3+ Treg. Eur J Immunol 2010; 40: 14252.
  • 29
    Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA. IL-2 is essential for TGF-beta to convert naive CD4+ CD25-cells to CD25+ Foxp3+ regulatory T cells and for expansion of these cells. J Immunol 2007; 178: 201827.
  • 30
    Erdman SE, Poutahidis T. Cancer inflammation and regulatory T cells. Int J Cancer 2010; 127: 76879.
  • 31
    Muller AJ, Sharma MD, Chandler PR et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A 2008; 105: 170738.
  • 32
    Munn DH, Sharma MD, Hou D et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004; 114: 28090.
  • 33
    Sharma MD, Baban B, Chandler P et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117: 257082.
  • 34
    Mucida D, Park Y, Kim G et al. Reciprocal Th17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007; 317: 56260.
  • 35
    Maynard C, Hatton RD, Helms WS, Oliver JR, Stephensen CB, Weaver CT. Contrasting roles for all-trans retinoic acid in TGF-b-meidated induction of Foxp3 and IL-10 genes in developing regulatory T cells. J Exp Med 2009; 206: 21319.
  • 36
    Itoh A, Isoda K, Kondoh M et al. Hepatoprotective effect of syringic acid and vanillic acid on concanavalin a-induced liver injury. Biol Pharm Bull 2009; 32: 12159.